JP2013540823A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013540823A5 JP2013540823A5 JP2013536811A JP2013536811A JP2013540823A5 JP 2013540823 A5 JP2013540823 A5 JP 2013540823A5 JP 2013536811 A JP2013536811 A JP 2013536811A JP 2013536811 A JP2013536811 A JP 2013536811A JP 2013540823 A5 JP2013540823 A5 JP 2013540823A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- piperazin
- yloxy
- benzamide
- chlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 4-{[2- (4-chlorophenyl) -4,4-dimethylcyclohex-1-en-1-yl] methyl} piperazin-1-yl Chemical group 0.000 claims 58
- 239000007962 solid dispersion Substances 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 38
- 238000000034 method Methods 0.000 claims 15
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 9
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 7
- 239000002904 solvent Substances 0.000 claims 7
- 229920003169 water-soluble polymer Polymers 0.000 claims 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- 238000002441 X-ray diffraction Methods 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000008180 pharmaceutical surfactant Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 230000001613 neoplastic effect Effects 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 5
- 239000000758 substrate Substances 0.000 claims 5
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 4
- WKULGVVLSQGJTK-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[(4-hydroxy-4-methylcyclohexyl)methylamino]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCC(C)(O)CC1 WKULGVVLSQGJTK-UHFFFAOYSA-N 0.000 claims 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 4
- 239000008186 active pharmaceutical agent Substances 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 3
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical compound OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 claims 3
- 229920002554 vinyl polymer Polymers 0.000 claims 3
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 claims 2
- NKITUFNNDFPWII-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NC(CC1)CCC1N1CCOCC1 NKITUFNNDFPWII-UHFFFAOYSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 claims 2
- TYERRNIXCPPQQD-UHFFFAOYSA-N N-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C(C1=CC=CC=C1)(=O)NOC=1C=C2C(=NC=1)NC=C2 TYERRNIXCPPQQD-UHFFFAOYSA-N 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000005157 alkyl carboxy group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 229920001531 copovidone Polymers 0.000 claims 2
- 229920000578 graft copolymer Polymers 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims 2
- 239000011118 polyvinyl acetate Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010061252 Intraocular melanoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims 1
- 206010061336 Pelvic neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 1
- 201000005746 Pituitary adenoma Diseases 0.000 claims 1
- 206010061538 Pituitary tumour benign Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 claims 1
- 206010046392 Ureteric cancer Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000005969 Uveal melanoma Diseases 0.000 claims 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 229920003086 cellulose ether Polymers 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000024207 chronic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 210000001198 duodenum Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 229920001519 homopolymer Polymers 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 claims 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002575 ocular melanoma Diseases 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 208000021310 pituitary gland adenoma Diseases 0.000 claims 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 1
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 229920000058 polyacrylate Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229940068965 polysorbates Drugs 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
- 125000002053 thietanyl group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40851710P | 2010-10-29 | 2010-10-29 | |
| US61/408,517 | 2010-10-29 | ||
| PCT/US2011/058024 WO2012058392A1 (en) | 2010-10-29 | 2011-10-27 | Solid dispersions containing an apoptosis-inducing agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013540823A JP2013540823A (ja) | 2013-11-07 |
| JP2013540823A5 true JP2013540823A5 (OSRAM) | 2014-12-18 |
| JP6068352B2 JP6068352B2 (ja) | 2017-01-25 |
Family
ID=44947217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013536811A Active JP6068352B2 (ja) | 2010-10-29 | 2011-10-27 | アポトーシス誘発剤を含む固体分散体 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20120277210A1 (OSRAM) |
| EP (1) | EP2632436B1 (OSRAM) |
| JP (1) | JP6068352B2 (OSRAM) |
| KR (2) | KR102095698B1 (OSRAM) |
| CN (1) | CN103167867B (OSRAM) |
| AU (1) | AU2011319842B2 (OSRAM) |
| BR (1) | BR112013009093B1 (OSRAM) |
| CA (2) | CA2811805A1 (OSRAM) |
| ES (1) | ES2699205T3 (OSRAM) |
| IL (1) | IL225340A (OSRAM) |
| MX (1) | MX349533B (OSRAM) |
| NZ (1) | NZ608274A (OSRAM) |
| RU (1) | RU2598345C2 (OSRAM) |
| SG (2) | SG189471A1 (OSRAM) |
| TW (1) | TWI598333B (OSRAM) |
| WO (1) | WO2012058392A1 (OSRAM) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| EP2632436B1 (en) * | 2010-10-29 | 2018-08-29 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| WO2012071336A1 (en) | 2010-11-23 | 2012-05-31 | Abbott Laboratories | Salts and crystalline forms of an apoptosis-inducing agent |
| PT2642999T (pt) | 2010-11-23 | 2017-01-05 | Abbvie Ireland Unlimited Co | Métodos de tratamento que utilizam inibidores seletivos de bcl-2 |
| EP2739269A2 (en) * | 2011-08-01 | 2014-06-11 | Ranbaxy Laboratories Limited | Dissolution enhanced controlled drug delivery system for poorly water soluble drugs |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| US20140335074A1 (en) | 2011-12-13 | 2014-11-13 | Buck Institute For Research On Aging | Methods for improving medical therapies |
| HK1212240A1 (en) | 2012-09-07 | 2016-06-10 | 吉宁特有限公司 | Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| US9006438B2 (en) | 2013-03-13 | 2015-04-14 | Abbvie Inc. | Processes for the preparation of an apoptosis-inducing agent |
| PE20151809A1 (es) | 2013-03-13 | 2015-12-25 | Abbvie Inc | Procesos para la preparacion de un agente inductor de la apoptosis |
| US20140275082A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| JP6232262B2 (ja) * | 2013-11-13 | 2017-11-15 | アクアス株式会社 | 徐放性を有する固形水処理剤、およびその製造方法 |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| US9993472B2 (en) | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
| ES2818110T3 (es) | 2014-02-28 | 2021-04-09 | Merck Sharp & Dohme | Tratamiento del cáncer con una combinación que comprende dinaciclib |
| US9238652B2 (en) * | 2014-03-04 | 2016-01-19 | Abbvie Inc. | Processes for the preparation of an apoptosis-inducing agent |
| RS62713B1 (sr) | 2014-08-11 | 2022-01-31 | Acerta Pharma Bv | Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| US11219625B2 (en) * | 2015-07-24 | 2022-01-11 | Yale University | Inhibitors of N-linked glycosylation and methods using same |
| JP6724136B2 (ja) | 2015-11-03 | 2020-07-15 | ジェネンテック， インコーポレイテッド | がん治療のためのＢｃｌ−２阻害剤及びＭＥＫ阻害剤の組み合わせ |
| WO2017156398A1 (en) | 2016-03-10 | 2017-09-14 | Assia Chemical Industries Ltd. | Solid state forms of venetoclax and processes for preparation of venetoclax |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| WO2018009444A1 (en) * | 2016-07-06 | 2018-01-11 | Concert Pharmaceuticals, Inc. | Deuterated venetoclax |
| JP6651180B2 (ja) * | 2016-08-05 | 2020-02-19 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ | Ｂｃｌ−２阻害剤としてのｎ−（フェニルスルホニル）ベンズアミドおよび関連化合物 |
| WO2018069941A2 (en) | 2016-10-14 | 2018-04-19 | Mylan Laboratories Limited | Polymorphic forms of venetoclax |
| CN106674085B (zh) * | 2016-12-20 | 2020-06-23 | 苏州汉德创宏生化科技有限公司 | N-1,3-二氟异丙基-4-氨基哌啶类化合物的合成方法 |
| CN110177788B (zh) | 2017-01-07 | 2023-03-24 | 重庆复创医药研究有限公司 | 作为bcl-2选择性凋亡诱导剂的化合物 |
| WO2018157803A1 (zh) * | 2017-02-28 | 2018-09-07 | 苏州科睿思制药有限公司 | 维奈妥拉的晶型及其制备方法 |
| WO2018192462A1 (en) * | 2017-04-18 | 2018-10-25 | Shanghai Fochon Pharmaceutical Co., Ltd. | Apoptosis-inducing agents |
| CN107501260B (zh) * | 2017-08-14 | 2019-08-13 | 郑州大学第一附属医院 | 一种Bcl-2抑制剂venetoclax以及中间体的制备方法 |
| CN116621860A (zh) | 2017-08-23 | 2023-08-22 | 广州麓鹏制药有限公司 | Bcl-2抑制剂 |
| CN108037196B (zh) * | 2017-11-23 | 2020-06-23 | 中山奕安泰医药科技有限公司 | 一种3-硝基-4-[[(四氢-2h-吡喃-4-基)甲基]氨基]苯磺酰胺的检测方法 |
| WO2019135253A1 (en) | 2018-01-02 | 2019-07-11 | Mylan Laboratories Limited | Polymorphic forms of venetoclax |
| WO2019139902A1 (en) | 2018-01-10 | 2019-07-18 | Zeno Royalties & Milestones, LLC | Benzamide compounds |
| CN111868059B (zh) * | 2018-03-30 | 2021-12-03 | 正大天晴药业集团股份有限公司 | 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂 |
| JP2021521138A (ja) | 2018-04-29 | 2021-08-26 | ベイジーン リミテッド | Ｂｃｌ−２阻害剤 |
| WO2020023435A1 (en) | 2018-07-24 | 2020-01-30 | Albany Molecular Research, Inc. | Venetoclax basic salts and processes for the purification of venetoclax |
| AU2019314624B2 (en) | 2018-07-31 | 2022-03-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of Bcl-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| CA3095699A1 (en) | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| MX2020009759A (es) | 2018-07-31 | 2020-10-08 | Ascentage Pharma Suzhou Co Ltd | Efecto antitumoral sinergico de un inhibidor de bcl-2 combinado con rituximab y/o bendamustina o un inhibidor de bcl-2 combinado con chop. |
| US11903950B2 (en) | 2018-08-22 | 2024-02-20 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| EP3858832A4 (en) | 2018-10-29 | 2022-06-08 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2 SELECTIVE INHIBITOR |
| CN109438441A (zh) * | 2018-11-30 | 2019-03-08 | 重庆三圣实业股份有限公司 | 一种维奈妥拉的制备方法及其产品 |
| US20230065740A1 (en) | 2018-12-28 | 2023-03-02 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| US12319689B2 (en) | 2019-05-24 | 2025-06-03 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor |
| WO2021007303A1 (en) * | 2019-07-10 | 2021-01-14 | Recurium Ip Holdings, Llc | Nanoparticle formulation of bcl-2 inhibitor |
| GB201911627D0 (en) * | 2019-08-14 | 2019-09-25 | Johnson Matthey Plc | Polymorph of venetoclax and method for preparing the polymorph |
| WO2021173523A1 (en) * | 2020-02-24 | 2021-09-02 | Newave Pharmaceutical Inc. | Hot melt extruded solid dispersions containing a bcl2 inhibitor |
| WO2021180040A1 (zh) * | 2020-03-12 | 2021-09-16 | 南京明德新药研发有限公司 | 苯并五元环类化合物 |
| AU2021256580A1 (en) | 2020-04-15 | 2022-09-29 | Beone Medicines I Gmbh | Bcl-2 inhibitor |
| MX2023000447A (es) * | 2020-07-07 | 2023-04-20 | Atxa Therapeutics Ltd | Antagonista de receptor de tromboxano formulaciones. |
| CN111643458A (zh) * | 2020-07-28 | 2020-09-11 | 青岛市肿瘤医院 | 一种治疗横纹肌肉瘤的药物制剂及其制备方法 |
| CN114057728A (zh) * | 2020-08-06 | 2022-02-18 | 北京诺诚健华医药科技有限公司 | 作为bcl-2抑制剂的杂环化合物 |
| MX2023003556A (es) * | 2020-09-29 | 2023-06-13 | Shenzhen Pharmacin Co Ltd | Composiciones farmaceuticas. |
| US20240016747A1 (en) * | 2020-11-25 | 2024-01-18 | Ascentage Pharma (Suzhou) Co., Ltd. | Solid dispersion, pharmaceutical preparations, preparation method, and application thereof |
| CN119421703A (zh) * | 2022-03-25 | 2025-02-11 | 深圳市药欣生物科技有限公司 | 无定形固体分散体和包含所述无定形固体分散体的药物组合物 |
| CN115925511B (zh) * | 2022-09-21 | 2024-03-29 | 苏州汉德创宏生化科技有限公司 | 一种中间体4,4-二氟环己醇的合成方法 |
| CN115260191B (zh) * | 2022-09-29 | 2022-12-27 | 上海睿跃生物科技有限公司 | 哌啶类化合物及其制备方法和应用 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2124821C (en) * | 1991-12-18 | 2003-10-07 | Isaac Ghebre-Sellassie | Novel solid pharmaceutical dispersions |
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| FR2736550B1 (fr) | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
| DK1019385T3 (da) | 1995-09-15 | 2004-05-24 | Upjohn Co | Aminoaryloxazolidinon-N-oxider |
| BRPI9707379C8 (pt) | 1996-02-09 | 2017-12-12 | Abbott Biotech Ltd | composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado. |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| ES2318899T3 (es) | 1998-07-06 | 2009-05-01 | Bristol-Myers Squibb Company | Bifenil sulfonamidas como antagonistas duales de los receptores de angiotensina y endotelina. |
| DE19913692A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
| DE19929361A1 (de) | 1999-06-25 | 2001-01-04 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
| US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| AU776933B2 (en) | 1999-12-28 | 2004-09-23 | Eisai R&D Management Co., Ltd. | Heterocyclic compounds having sulfonamide groups |
| US20020055631A1 (en) | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
| US6720338B2 (en) | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| UY26942A1 (es) | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| SK14642003A3 (sk) | 2001-06-06 | 2004-12-01 | Eli Lilly And Company | Benzoylsulfónamidy a sulfonylbenzamidíny ako protinádorové činidlá |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| CA2477350C (en) | 2002-02-26 | 2013-02-12 | Astrazeneca Ab | Novel crystalline forms of the anti-cancer compound zd1839 |
| ES2286406T3 (es) | 2002-02-26 | 2007-12-01 | Astrazeneca Ab | Formulacion farmaceutica de iressa que comprende un derivado de celulosa soluble en agua. |
| FR2836914B1 (fr) | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| MY129850A (en) | 2002-04-29 | 2007-05-31 | Merck Sharp & Dohme | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
| WO2005024636A1 (ja) | 2003-09-04 | 2005-03-17 | Hitachi Ulsi Systems Co., Ltd. | 半導体装置 |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| US7790190B2 (en) | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
| WO2005099353A2 (en) | 2004-04-19 | 2005-10-27 | Symed Labs Limited | A novel process for the preparation of linezolid and related compounds |
| JP2007536299A (ja) | 2004-05-04 | 2007-12-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｌｔｂ４アンタゴニトを含有する固形医薬形態 |
| PL1768967T3 (pl) | 2004-07-20 | 2009-09-30 | Symed Labs Ltd | Nowe związki pośrednie do wytwarzania linezolidu oraz związki pokrewne |
| CN101048140B (zh) | 2004-08-27 | 2013-06-19 | 拜尔保健公司 | 用于治疗癌症的药物组合物 |
| MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
| JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| CA2606147C (en) | 2005-05-12 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US20080300267A1 (en) | 2005-05-16 | 2008-12-04 | Barun Okram | Compounds and Compositions as Protein Kinase Inhibitors |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| PL1893612T3 (pl) | 2005-06-22 | 2012-01-31 | Plexxikon Inc | Pochodne pirolo-[2,3-b]pirydyny jako inhibitory kinazy białkowej |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| WO2008008375A2 (en) | 2006-07-14 | 2008-01-17 | Chemocentryx, Inc. | Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of inflammation |
| EP1880715A1 (en) | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
| US7799790B2 (en) | 2006-07-20 | 2010-09-21 | Helm Ag | Amorphous aripiprazole and process for the preparation thereof |
| KR100767349B1 (ko) * | 2006-08-01 | 2007-10-17 | 삼천당제약주식회사 | 페노피브레이트를 함유하는 경구용 약제 조성물 및 그의제조방법 |
| JP5277168B2 (ja) | 2006-09-05 | 2013-08-28 | アボット・ラボラトリーズ | 血小板過剰を治療するｂｃｌインヒビター |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| WO2008067164A2 (en) | 2006-11-15 | 2008-06-05 | Abbott Laboratories | Solid pharmaceutical dosage formulations |
| WO2008064116A2 (en) | 2006-11-16 | 2008-05-29 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| MX2009008465A (es) | 2007-02-15 | 2009-08-20 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos de taar1. |
| US8536157B2 (en) | 2007-04-13 | 2013-09-17 | The University Of Melbourne | Non-steroidal compounds |
| CA2686545C (en) | 2007-04-19 | 2010-11-02 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20110123482A1 (en) | 2007-10-01 | 2011-05-26 | The Johns Hopkins University | Methods of Treating Neurological Autoimmune Disorders with Cyclophosphamide |
| US20090137457A1 (en) | 2007-10-02 | 2009-05-28 | Concert Pharmaceuticals, Inc. | Pyrimidinedione derivatives |
| US8410124B2 (en) | 2007-10-18 | 2013-04-02 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| WO2009055006A1 (en) | 2007-10-26 | 2009-04-30 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| KR101585848B1 (ko) | 2007-11-16 | 2016-01-15 | 애브비 인코포레이티드 | 관절염의 치료 방법 |
| CA2708223A1 (en) | 2007-12-06 | 2009-06-11 | Andrew Krivoshik | Oral compositions of abt-263 for treating cancer |
| WO2009091912A2 (en) | 2008-01-15 | 2009-07-23 | Abbott Laboratories | Improved mammalian expression vectors and uses thereof |
| CN101548960B (zh) | 2008-04-01 | 2012-11-07 | 沈阳药科大学 | 高溶出度口服联苯双酯胶囊及其制备方法 |
| MY160340A (en) | 2008-10-07 | 2017-02-28 | Astrazeneca Uk Ltd | Pharmaceutical formulation 514 |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP3666758A1 (en) * | 2008-12-05 | 2020-06-17 | AbbVie Inc. | Process for the preparation of a sulfonamide derivative |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| WO2010077740A2 (en) | 2008-12-09 | 2010-07-08 | Cytokine Pharmasciences, Inc. | Novel antiviral compounds, compositions, and methods of use |
| WO2010072734A2 (en) | 2008-12-23 | 2010-07-01 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Targeting prodrugs and compositions for the treatment of gastrointestinal diseases |
| MX2011007681A (es) | 2009-01-19 | 2011-08-08 | Abbott Lab | Agentes inducidores de apoptosis para el tratamiento del cancer y enfermedades inmunes y autoinmunes. |
| CN104945311A (zh) | 2009-01-19 | 2015-09-30 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| RU2535347C3 (ru) * | 2009-05-26 | 2019-05-14 | ЭббВи Айэленд Анлимитед Компани | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI471321B (zh) * | 2009-06-08 | 2015-02-01 | 亞培公司 | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| PE20110679A1 (es) | 2009-06-11 | 2011-10-20 | Abbvie Bahamas Ltd | Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| EP2632436B1 (en) | 2010-10-29 | 2018-08-29 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| WO2012071336A1 (en) | 2010-11-23 | 2012-05-31 | Abbott Laboratories | Salts and crystalline forms of an apoptosis-inducing agent |
| PT2642999T (pt) | 2010-11-23 | 2017-01-05 | Abbvie Ireland Unlimited Co | Métodos de tratamento que utilizam inibidores seletivos de bcl-2 |
-
2011
- 2011-10-27 EP EP11782300.5A patent/EP2632436B1/en active Active
- 2011-10-27 US US13/282,773 patent/US20120277210A1/en not_active Abandoned
- 2011-10-27 RU RU2013124824/15A patent/RU2598345C2/ru active
- 2011-10-27 BR BR112013009093-6A patent/BR112013009093B1/pt active IP Right Grant
- 2011-10-27 CN CN201180052601.1A patent/CN103167867B/zh active Active
- 2011-10-27 IL IL225340A patent/IL225340A/en active IP Right Grant
- 2011-10-27 ES ES11782300T patent/ES2699205T3/es active Active
- 2011-10-27 KR KR1020137013699A patent/KR102095698B1/ko active Active
- 2011-10-27 CA CA2811805A patent/CA2811805A1/en not_active Abandoned
- 2011-10-27 AU AU2011319842A patent/AU2011319842B2/en active Active
- 2011-10-27 SG SG2013029772A patent/SG189471A1/en unknown
- 2011-10-27 WO PCT/US2011/058024 patent/WO2012058392A1/en not_active Ceased
- 2011-10-27 JP JP2013536811A patent/JP6068352B2/ja active Active
- 2011-10-27 MX MX2013004778A patent/MX349533B/es active IP Right Grant
- 2011-10-27 NZ NZ608274A patent/NZ608274A/en unknown
- 2011-10-27 CA CA3152557A patent/CA3152557A1/en active Pending
- 2011-10-27 KR KR1020187014015A patent/KR20180059560A/ko active Pending
- 2011-10-27 SG SG10201801794WA patent/SG10201801794WA/en unknown
- 2011-10-28 TW TW100139446A patent/TWI598333B/zh active
-
2014
- 2014-11-10 US US14/537,392 patent/US10213433B2/en active Active
-
2019
- 2019-01-03 US US16/239,199 patent/US20190275051A1/en not_active Abandoned
-
2021
- 2021-06-07 US US17/341,158 patent/US20220125796A1/en not_active Abandoned
-
2024
- 2024-08-20 US US18/809,439 patent/US20250161318A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013540823A5 (OSRAM) | ||
| EP3219308A1 (en) | Melt-extruded solid dispersions containing an apoptosis-inducing agent | |
| RU2013124824A (ru) | Твердые дисперсии, содержащие средства, вызывающие апоптоз | |
| JP2014139226A5 (OSRAM) | ||
| US7662823B2 (en) | Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives | |
| KR101045154B1 (ko) | 치환된 아자인돌옥소아세틱 피페라진 유도체의 조성물 및항바이러스 활성 | |
| CA2520124A1 (en) | Use of benzazole compounds for immunopotentiation | |
| JP2016512825A5 (OSRAM) | ||
| JP2017048219A5 (OSRAM) | ||
| SI2982366T1 (en) | A pharmaceutical dosage form for the oral administration of an inhibitor of the Bcl-2 family | |
| KR20160048807A (ko) | 과증식성 질병의 치료에서 사용하기 위한 mek 억제제 및 erk 억제제의 조합 | |
| JP2009515814A5 (OSRAM) | ||
| JP2013503139A (ja) | タンパク質キナーゼ阻害剤としての化合物および組成物 | |
| JP2010516701A5 (OSRAM) | ||
| CN105120868A (zh) | 组合治疗 | |
| JP2010516700A5 (OSRAM) | ||
| IL295803A (en) | Hot melt extruded solid dispersions containing a bcl2 inhibitor | |
| JP2003512327A5 (OSRAM) | ||
| JP2016535095A5 (OSRAM) | ||
| JP2017522349A5 (OSRAM) | ||
| JP2014527997A5 (OSRAM) | ||
| JP2007518781A5 (OSRAM) | ||
| JPWO2021007386A5 (OSRAM) | ||
| JP2005535597A5 (OSRAM) | ||
| JPWO2021173523A5 (OSRAM) |